Showing results (151-160 of 198) with videos related to
Sort By:
Pageof 20
Nature Cancer|May 13, 2025
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumorsFeiyu Chen, Haoyan Li, Yin Wang, et al.Cancer Research|June 30, 2022
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2Haoyan Li, Yin Wang, Kevin Lin, et al.Genome Research|November 25, 2024
A deconvolution framework that uses single-cell sequencing plus a small benchmark data set for accurate analysis of cell type ratios in complex tissue samplesShuai Guo, Xiaoqian Liu, Xuesen Cheng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate CancerPaul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLCSteven H Lin, Yan Lin, Luyang Yao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.Pageof 20